Loading...
CTXR logo

Citius Pharmaceuticals, Inc.NasdaqCM:CTXR Rapporto sulle azioni

Cap. di mercato US$19.2m
Prezzo delle azioni
US$0.70
US$5
86.0% sottovalutato sconto intrinseco
1Y-1.4%
7D26.5%
1D
Valore del portafoglio
​
Vista

Citius Pharmaceuticals, Inc.

Report azionario NasdaqCM:CTXR

Capitalizzazione di mercato: US$19.2m

Citius Pharmaceuticals (CTXR) Panoramica del titolo

Citius Pharmaceuticals, Inc. è una società biofarmaceutica che si concentra sullo sviluppo e sulla commercializzazione di prodotti per l'assistenza critica. Maggiori dettagli

CTXR analisi fondamentale
Punteggio fiocco di neve
Valutazione3/6
Crescita futura5/6
Prestazioni passate0/6
Salute finanziaria5/6
Dividendi0/6

Premi

Si prevede che gli utili cresceranno del 55.87% all'anno

Negoziato a un buon valore rispetto ai pari e al settore

Analisi del rischio

Gli azionisti sono stati sostanzialmente diluiti nell'ultimo anno

Prezzo delle azioni altamente volatile negli ultimi 3 mesi rispetto al mercato US

Non ha una capitalizzazione di mercato significativa ( $19M )


CTXR Community Fair Values

Create Narrative

See what 17 others think this stock is worth. Follow their fair value or set your own to get alerts.

View all narratives

Concorrenti di Citius Pharmaceuticals, Inc.

Storia dei prezzi e prestazioni

Riepilogo dei massimi, dei minimi e delle variazioni dei prezzi delle azioni per Citius Pharmaceuticals
Prezzi storici delle azioni
Prezzo attuale dell'azioneUS$0.70
Massimo di 52 settimaneUS$2.48
Minimo di 52 settimaneUS$0.48
Beta1.05
Variazione di 1 mese-8.95%
Variazione a 3 mesi-6.28%
Variazione di 1 anno-1.41%
Variazione a 3 anni-97.45%
Variazione a 5 anni-98.81%
Variazione dall'IPO-99.81%

Notizie e aggiornamenti recenti

Recent updates

Articolo di analisi • Apr 06

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Needs To Drive Business Growth Carefully

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Dec 08

We're Keeping An Eye On Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Rate

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, although Amazon.com...
Articolo di analisi • Aug 01

Will Citius Pharmaceuticals (NASDAQ:CTXR) Spend Its Cash Wisely?

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Articolo di analisi • Apr 12

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Articolo di analisi • Dec 25

Here's Why We're Watching Citius Pharmaceuticals' (NASDAQ:CTXR) Cash Burn Situation

Even when a business is losing money, it's possible for shareholders to make money if they buy a good business at the...
Seeking Alpha • Sep 28

Citius Pharma submits biologics license application to FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Wednesday said it had submitted a biologics license application (BLA) to the U.S. FDA for its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. According to CTXR, I/ONTAK (denileukin diftitox) is a purified and more bioactive formulation of previously FDA-approved therapy ONTAK. The BLA submission was supported by results from a phase 3 study. The submission comes after CTXR held a pre-BLA meeting with the FDA in July. The company in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. "The BLA filing for denileukin diftitox marks the first of our pipeline candidates to be submitted for FDA approval," CTXR CEO Leonard Mazur said in Wednesday's statement. Citius Pharmaceuticals (CTXR) stock -0.9% to $1.17 in premarket trading.
Seeking Alpha • Aug 11

Citius Pharmaceuticals GAAP EPS of -$0.06

Citius Pharmaceuticals press release (NASDAQ:CTXR): Q3 GAAP EPS of -$0.06. The company has reported $48.0 million in cash and cash equivalents as of June 30, 2022 to support ongoing programs through August 2023
Articolo di analisi • Aug 05

Here's Why Citius Pharmaceuticals (NASDAQ:CTXR) Must Use Its Cash Wisely

We can readily understand why investors are attracted to unprofitable companies. For example, although...
Seeking Alpha • Jul 12

Citius holds pre-biologics license application meeting with FDA for immunotherapy I/ONTAK

Citius Pharmaceuticals (NASDAQ:CTXR) on Tuesday said it had held a pre-biologics license application (BLA) meeting with the U.S. FDA to discuss its I/ONTAK immunotherapy for the treatment of cutaneous T-cell lymphoma, a rare type of cancer. "Based on the FDA's pre-BLA meeting comments, we intend to move forward with our planned BLA submission for I/ONTAK in the second half of 2022," said CTXR CEO Leonard Mazur. The purpose of the pre-BLA meeting was to discuss the content and acceptability of the company's anticipated BLA for I/ONTAK. Citius (CTXR) in May had said that it planned to form a new company focused on developing and commercializing I/ONTAK, with an IPO planned for H2 2022. CTXR stock +1.3% to $0.92 in premarket trading.
Seeking Alpha • Jul 05

Citius Pharmaceuticals: Hoping For A Turnaround Strategy

Citius Pharmaceuticals is yet to release test results a year after it was granted positive recommendation by the Independent Data Monitoring Committee (IDMC) to proceed with the planned trial. With the help of Biorasi, Citius could reach full patient enrolment by the end of 2022, as earlier indicated. Calculations show that Citius' current cash reserves of $55.8 million will only last the company until December 2022, just when it is expected to complete patient enrolment. There is a buy-out possibility after the company announced its intention to spin-off I/Ontak less than a year after license acquisition. Late-stage biopharmaceuticals company Citius Pharmaceuticals, Inc. (CTXR) informed investors that it had selected Biorasi to help it expand its Phase 3 Mino-Lok trial to clinical sites outside the U.S. Well, that formed one of the main highlights of Q2 2022, with investors yet to hear any news about patient enrolment almost 2 months after Biorasi's appointment. Still, there is a lot of excitement among investors with Citius expected to file its biologics license application ((BLA)) for I/ONTAK with the U.S. Food and Drug Administration ((FDA)) later in the second half of 2022. Thesis In this article, I will explain why I am raising my rating of CTXR to hold from sell. The plan to spin off I/Ontak as a standalone company appears to be a strategic move to spearhead growth and attract new investors to the company. As a pure-play oncology-focused biopharmaceutical project, the new company may leverage past mistakes that have delayed the release of topline data for Mino-Lok. Further, new acquisitions are in the offing, especially since the company's finances are inadequate to sustain the company for the next 12 months. Earlier Assessment In my previous article on CTXR, I expressed my concerns over the company's rush to buy E7777 where it burnt a significant amount of cash. Citius is yet to recover, and it is now on the verge of forming a new company to develop and commercialize I/Ontak. This decision comes as no surprise since it had already completed the Phase 3 trial in December 2021. Additionally, the pipeline development for the two main drug candidates: Mino-Lok and E7777 were on different trajectories. Apart from I/Ontak and Mino-Lok, Citius also has in its pipeline Halo-lido, Mino-Wrap, and a Stem cell platform. At the moment, the market is in a bear mode with investors eagerly waiting for some good news within the pipeline development to squeeze the shorts. For Citius, it has been a long time coming. In July 2021, CTXR announced a positive recommendation by the Independent Data Monitoring Committee ((IDMC)) to proceed with the planned Mino-Lok Phase 3 Trial. One year later, the company is yet to release test results. However, with the entry of Biorasi, we expect the company to fast-track patient enrolment. Overview of Patient enrolment and Phase 3 Trial Dynamics The total number of patients planned for Mino-Lok's phase 3 trial is 144, distributed as 1:1 to the standard of care ((SOC)) which is antibiotics. The objective of this trial (as noted in our earlier report) is to evaluate Mino-Lok's efficacy in salvaging colonized central venous catheters in patients with catheter-related or central line-associated bloodstream infection (CRBSI/ CLABSI). This evaluation is compared to the SOC of using antibiotics. In this trial, the protocol will be focused on reaching 92 catheter failure events that also correspond to the 144 patients. Albeit, the company is yet to disclose how many patients it has tested so far and how many events are in the balance. The primary endpoint is the time until catheter failure occurs, expressed in days from randomization into one of the two study arms. Simply put, this means that a patient with a catheter develops a bacterial infection, is subsequently assigned to one of the two study arms, and from then on, the time in days until the catheter needs to be replaced is noted. In the description of the study, this is given as a time frame of 6 weeks. To be able to show the statistical superiority of Mino-Lok over SOC, the time to catheter failure was defined as at least 38 days for Mino-Lok versus 21 days for SOC. The trial started in February 2018 and reached 40% enrollment in September 2019. The next 50% were reached in February 2020 and later 80% were reached in June 2021. This fits pretty nicely to a rate of 2% enrollment per month. It is interesting to note here that the normally increasing speed of enrollment throughout a study due to clinics being added and the slowdown of the study due to the COVID-19 pandemic have balanced each other out. However, there was a fundamental change by Q4 2021. Despite the increasing number of patients during the Covid19 pandemic, the company still expected a prolonged trial that would affect enrolment. This problem necessitated the recruitment of Biorasi. Citius CEO, Myron Holubiak was optimistic about the company's accomplishments in 2022, despite the apparent delays. He stated, As we move into 2022, we anticipate multiple positive milestones. These include accelerated enrollment and completion of the Mino-Lok trial during the year, topline results in the first half of 2022 for the recently completed I/ONTAK (E7777) Pivotal Phase 3 trial followed by a BLA submission in the second half of the year." Before this date, CTXR always said that topline data for Mino-Lok will be published in 2022, suddenly it changed and only completion of the trial (meaning full enrollment) is planned. Right now, there is no further update on the actual state of the enrollment. In February, CTXR again stated that trial completion will be reached in 2022 leaving open the final date for topline data. Enrollment must be higher than 80% but seems to be very slow. CTXR plans to reach full enrollment by the end of 2022. Now, with the help of Biorasi, this could be fastened up. But still, CTXR plans year-end 2022 for full enrollment and as long as we have no further update, we have to calculate with this. Questions are: What happened to the speed of the enrollment in H2 2021? Why was Biorasi asked for help so late? One could have added clinics in other countries also right from the beginning to keep the Phase 3 trial short. I have no idea why they waited so long for this step. Of special note is that the FDA does not require a certain number of patients but wants to see two adequate and well-designed clinical trials. With regards to Mino-Lok, the completed Phase 2 and the ongoing Phase 3 trials will be sufficient. The number of patients per trial strongly depends on the indication, the trial design and the statistical calculations planned and thus are different for every trial. The planned 144 patients in Phase 3 is enough for FDA approval if the results are good, and statistically significant to prove that Mino-Lok is safe. So what is remaining as far as Mino-Lok is concerned? In presenting its phase 3 topline data, Citius will first hold a Pre-NDA (New Drug Application) meeting with the FDA to talk about the NDA filing and if data are enough. It's the first check by FDA if there are enough data. Sometimes FDA demands additional trials, which can be small or even a full Phase 3 trial. Also, check with FDA if any designations will shorten the review process of the FDA from 10 to 6 months. Mino-Lok already was granted fast-track designation by the FDA meaning that their review process will be only 6 months. Writing the NDA application is a time-based process. It must contain all clinical, and pre-clinical data and manufacturing details. It is expected that it will take at least 6 months from filing to submission of data to the FDA (after the release of topline data). After filing the NDA, the FDA takes 2 months to approve or reject the data. After approval, the FDA needs another 6 months (with fast-track designation, otherwise it takes 10 months) to check the NDA and decide about the approval of Mino-Lok. Thus, in general, CTXR has to prepare everything about Mino-Lok including all results and data but also how it is manufactured and the corresponding documents that prove good manufacturing practice and quality control mechanisms, etc. This means that from topline data onward I believe CTXR will need at least 6 months until NDA submission, followed by a total of 8 months (2 months needed by the FDA to accept the filing and 6 months to review the NDA) until the FDA will finally decide if Mino-Lok is approved. This means with topline data in H1 2023, approval could be in mid-2024. Selling Halo-Lido? Investors are looking forward to CTXR's selling of Halo-Lido, especially after the Phase 2B trial. Whether it will be a possibility or not remains a subject under discussion. Still, the company desperately needs financial backup. Before we address the financial standpoint, we need to underscore the fact that the FDA is yet to approve a prescription drug for the treatment of hemorrhoids. Once approved, Halo-Lido could become the first drug to treat hemorrhoids in the US. Citius Chairman, Leonard Mazur confirmed that the company had received several interested buyers back in 2021. We can speculate that one of the buyers may be interested in buying out Citius but may not be interested in I/Ontak or E7777- the reason for the spin-off.
Seeking Alpha • Apr 13

Critical Care Biopharma - Citius Pharmaceuticals

Citius Pharmaceuticals is a late-stage biopharma focused on critical care products. Preventing shareholder dilution. Resumption of clinical trials after COVID-19.
Seeking Alpha • Mar 28

Citius: 2022 Is A Year Of Catalysts

5 Active Programs With Near Term Catalysts. I/ONTEK Topline Data Release Expected As Early As April. Price Target of $10.
Articolo di analisi • Dec 04

We Think Citius Pharmaceuticals (NASDAQ:CTXR) Can Afford To Drive Business Growth

Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
Seeking Alpha • Sep 26

Citius Pharmaceuticals, Inc.: Burning Cash Before Commercialization

Citius stock price reacted to no safety concerns identified by the DMC, to surge 102.86% (YoY) and +108.82% (YTD). Citius has prioritized E7777 threatening to derail the company's progression with Mino-Lok. Continual medical development may overthrow the use of CVCs due to the high mortality rate of 12%-25% associated with CLABSI. With a cash balance of $115.7 million, Citius will likely incur a loss in the E7777 transaction. It requires an upfront payment of $40 million and milestone payments of up to $110 million.
Articolo di analisi • Aug 28

Companies Like Citius Pharmaceuticals (NASDAQ:CTXR) Are In A Position To Invest In Growth

There's no doubt that money can be made by owning shares of unprofitable businesses. By way of example, Citius...

Rendimenti per gli azionisti

CTXRUS PharmaceuticalsUS Mercato
7D26.5%5.4%1.2%
1Y-1.4%44.3%28.7%

Ritorno vs Industria: CTXR ha avuto una performance inferiore rispetto al US Pharmaceuticals che ha registrato un rendimento 44.3 % nell'ultimo anno.

Rendimento vs Mercato: CTXR ha avuto una performance inferiore al mercato US che ha registrato un rendimento 28.7 % nell'ultimo anno.

Volatilità dei prezzi

Is CTXR's price volatile compared to industry and market?
CTXR volatility
CTXR Average Weekly Movement19.1%
Pharmaceuticals Industry Average Movement9.9%
Market Average Movement7.2%
10% most volatile stocks in US Market16.4%
10% least volatile stocks in US Market3.1%

Prezzo delle azioni stabile: Negli ultimi 3 mesi il prezzo delle azioni di CTXR è stato volatile rispetto al mercato US.

Volatilità nel tempo: La volatilità settimanale ( 19% ) di CTXR è rimasta stabile nell'ultimo anno, ma è comunque superiore al 75% delle azioni US.

Informazioni sull'azienda

FondatoI dipendentiAMMINISTRATORE DELEGATOSito web
200723Leonard Mazurcitiuspharma.com

Citius Pharmaceuticals, Inc. è un'azienda biofarmaceutica che si concentra sullo sviluppo e la commercializzazione di prodotti per l'assistenza critica. LYMPHIR, un prodotto approvato dalla FDA, è un'immunoterapia mirata per il trattamento del linfoma cutaneo a cellule T. L'azienda ha una pipeline in fase avanzata che comprende Mino-Lok, una soluzione di blocco antibiotico per il trattamento del linfoma cutaneo. La pipeline dell'azienda, in fase avanzata, comprende Mino-Lok, una soluzione di blocco antibiotico per il trattamento dei pazienti con infezioni del flusso sanguigno legate ai cateteri; Halo-Lido, una formulazione topica a base di corticosteroidi e lidocaina per fornire un sollievo antinfiammatorio e anestetico alle persone che soffrono di emorroidi; e NoveCite, una terapia a base di cellule staminali mesenchimali per il trattamento dell'ARDS.

Citius Pharmaceuticals, Inc. Riepilogo dei fondamenti

Come si confrontano gli utili e i ricavi di Citius Pharmaceuticals con la sua capitalizzazione di mercato?
CTXR statistiche fondamentali
Capitalizzazione di mercatoUS$19.25m
Utili (TTM)-US$46.20m
Ricavi(TTM)US$5.61m
3.4x
Rapporto P/S
-0.4x
Rapporto P/E

CTXR è sopravvalutato?

Vedi Fair Value e analisi di valutazione

Utili e ricavi

Statistiche chiave sulla redditività dall'ultima relazione sugli utili (TTM)
CTXR Conto economico (TTM)
RicaviUS$5.61m
Costo del fatturatoUS$1.12m
Profitto lordoUS$4.49m
Altre speseUS$50.69m
Utili-US$46.20m

Ultimi utili riportati

Mar 31, 2026

Prossima data di guadagno

n/a

Utile per azione (EPS)-1.68
Margine lordo80.07%
Margine di profitto netto-823.34%
Rapporto debito/patrimonio netto0%

Come si è comportato CTXR nel lungo periodo?

Vedi performance storica e confronto

Analisi aziendale e situazione dei dati finanziari

DatiUltimo aggiornamento (ora UTC)
Analisi dell'azienda2026/05/26 12:11
Prezzo dell'azione a fine giornata2026/05/22 00:00
Utili2026/03/31
Utili annuali2025/09/30

Fonti dei dati

I dati utilizzati nella nostra analisi aziendale provengono da S&P Global Market Intelligence LLC. I seguenti dati sono utilizzati nel nostro modello di analisi per generare questo report. I dati sono normalizzati, il che può comportare un ritardo nella disponibilità della fonte.

PacchettoDatiTempisticaEsempio Fonte USA *
Dati finanziari della società10 anni
  • Conto economico
  • Rendiconto finanziario
  • Bilancio
Stime di consenso degli analisti+3 anni
  • Previsioni finanziarie
  • Obiettivi di prezzo degli analisti
Prezzi di mercato30 anni
  • Prezzi delle azioni
  • Dividendi, scissioni e azioni
Proprietà10 anni
  • Top azionisti
  • Insider trading
Gestione10 anni
  • Team di leadership
  • Consiglio di amministrazione
Sviluppi principali10 anni
  • Annunci aziendali

* Esempio per i titoli statunitensi, per i titoli non statunitensi si utilizzano forme e fonti normative equivalenti.

Se non specificato, tutti i dati finanziari si basano su un periodo annuale ma vengono aggiornati trimestralmente. Si tratta dei cosiddetti dati TTM (Trailing Twelve Month) o LTM (Last Twelve Month). Per saperne di più.

Modello di analisi e Snowflake

I dettagli del modello di analisi utilizzato per generare questo report sono disponibili sulla nostra pagina Github; abbiamo anche guide su come utilizzare i nostri report e tutorial su Youtube.

Scoprite il team di livello mondiale che ha progettato e realizzato il modello di analisi Simply Wall St.

Metriche di settore e industriali

Le nostre metriche di settore e di sezione sono calcolate ogni 6 ore da Simply Wall St; i dettagli del nostro processo sono disponibili su Github.

Fonti analitiche

Citius Pharmaceuticals, Inc. è coperta da 4 analisti. 2 di questi analisti ha fornito le stime di fatturato o di utile utilizzate come input per il nostro report. Le stime degli analisti vengono aggiornate nel corso della giornata.

AnalistaIstituzione
Jason KolbertD. Boral Capital LLC.
Swayampakula RamakanthH.C. Wainwright & Co.
Jason McCarthyMaxim Group